WO2006078911A3 - Gitr antibodies for the diagnosis of nsclc - Google Patents

Gitr antibodies for the diagnosis of nsclc Download PDF

Info

Publication number
WO2006078911A3
WO2006078911A3 PCT/US2006/002050 US2006002050W WO2006078911A3 WO 2006078911 A3 WO2006078911 A3 WO 2006078911A3 US 2006002050 W US2006002050 W US 2006002050W WO 2006078911 A3 WO2006078911 A3 WO 2006078911A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
diagnosis
cancers
gitr antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/002050
Other languages
French (fr)
Other versions
WO2006078911A2 (en
Inventor
Beverly Teicher
Shrinivas Shankara
Bruce Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CA002592330A priority Critical patent/CA2592330A1/en
Priority to EP06719028A priority patent/EP1856281A2/en
Priority to AU2006206343A priority patent/AU2006206343A1/en
Priority to JP2007552289A priority patent/JP2008527998A/en
Priority to BRPI0606685-2A priority patent/BRPI0606685A2/en
Publication of WO2006078911A2 publication Critical patent/WO2006078911A2/en
Publication of WO2006078911A3 publication Critical patent/WO2006078911A3/en
Priority to IL184343A priority patent/IL184343A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of cancers, e.g., NSCLC, of epithelial origin, e.g., lung, ovarian, breast, prostate and colon cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of antigens associated with these cancers and malignancies.
PCT/US2006/002050 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc Ceased WO2006078911A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002592330A CA2592330A1 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc
EP06719028A EP1856281A2 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc
AU2006206343A AU2006206343A1 (en) 2005-01-19 2006-01-19 GITR antibodies for the diagnosis of NSCLC
JP2007552289A JP2008527998A (en) 2005-01-19 2006-01-19 GITR antibody for diagnosis of NSCLC
BRPI0606685-2A BRPI0606685A2 (en) 2005-01-19 2006-01-19 gitr antibodies for diagnosis of nsclc
IL184343A IL184343A0 (en) 2005-01-19 2007-07-02 Gitr antibodies for the diagnosis of nsclc

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64534905P 2005-01-19 2005-01-19
US60/645,349 2005-01-19

Publications (2)

Publication Number Publication Date
WO2006078911A2 WO2006078911A2 (en) 2006-07-27
WO2006078911A3 true WO2006078911A3 (en) 2007-06-28

Family

ID=36692925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002050 Ceased WO2006078911A2 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc

Country Status (8)

Country Link
EP (1) EP1856281A2 (en)
JP (1) JP2008527998A (en)
CN (1) CN101133167A (en)
AU (1) AU2006206343A1 (en)
BR (1) BRPI0606685A2 (en)
CA (1) CA2592330A1 (en)
IL (1) IL184343A0 (en)
WO (1) WO2006078911A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241992B2 (en) 2007-07-12 2016-01-26 Gitr, Inc. Combination therapies employing GITR binding molecules

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5238936B2 (en) 2005-03-25 2013-07-17 ジーアイティーアール，インク． GITR binding molecules and uses thereof
IN2015DN02826A (en) 2009-09-03 2015-09-11 Merck Sharp & Dohme
KR101566539B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th2 cell and use thereof
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
PL3151921T3 (en) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP5995207B2 (en) * 2014-11-28 2016-09-21 学校法人 学習院 Boron-containing porphyrin derivatives
EP3304079B1 (en) * 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MX2018006072A (en) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof.
MX2018010851A (en) * 2016-03-08 2019-02-07 Janssen Biotech Inc Gitr antibodies, methods, and uses.
JP7473339B2 (en) * 2017-03-07 2024-04-23 エフ． ホフマン－ラ ロシュ アーゲー Methods for discovering alternative antigen-specific antibody variants
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CN109777872B (en) * 2017-11-15 2021-04-02 北京大学 T cell subsets and their signature genes in lung cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
WO2000050459A1 (en) * 1999-02-24 2000-08-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) * 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6509173B1 (en) * 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) * 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2000050459A1 (en) * 1999-02-24 2000-08-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241992B2 (en) 2007-07-12 2016-01-26 Gitr, Inc. Combination therapies employing GITR binding molecules

Also Published As

Publication number Publication date
JP2008527998A (en) 2008-07-31
WO2006078911A2 (en) 2006-07-27
AU2006206343A1 (en) 2006-07-27
EP1856281A2 (en) 2007-11-21
CN101133167A (en) 2008-02-27
CA2592330A1 (en) 2006-07-27
BRPI0606685A2 (en) 2009-07-14
IL184343A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
PH12012501016A1 (en) Novel genomic biomarkers for irritable bowel syndrome diagnosis
WO2006012646A3 (en) Amacr cancer markers
WO2012006632A3 (en) Lung cancer biomarkers and uses thereof
GB2478441A (en) Lung cancer biomarkers and uses thereof
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
EA201390638A8 (en) ENTRANCE AND IDENTIFICATION OF FETAL CELLS IN MATERNAL BLOOD AND LIGANDS FOR SUCH APPLICATION
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
DK2211180T3 (en) Use of protein SATB2 as a marker to distinguish colorectal cancer from other cancers
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
EA201390694A1 (en) METHODS OF TREATING CANCER
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2012085574A3 (en) Detection of acute myeloid leukaemia
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2012006394A3 (en) Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer
BRPI0606685A2 (en) gitr antibodies for diagnosis of nsclc
WO2007141043A3 (en) Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma
WO2002080844A3 (en) Novel bgp compounds for therapy and diagnosis and methods for using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680006891.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006206343

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2592330

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 184343

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006719028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008691

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007552289

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006206343

Country of ref document: AU

Date of ref document: 20060119

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2899/KOLNP/2007

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: PI0606685

Country of ref document: BR

Kind code of ref document: A2